Alison Stopeck

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alison Stopeck sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 2 completed early-phase tilt upper quartile by trial count

Alison Stopeck: 3 sponsored US clinical trials, 1 recruiting.

Alison Stopeck sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced Breast Cancer, with 1 trials.

Upper-quartile sponsor footprint

Alison Stopeck sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Alison Stopeck pipeline

1 recruiting of 3 indexed (33% open); 2 completed (67%).

Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).

Top condition: Locally Advanced Breast Cancer (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alison Stopeck: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Alison Stopeck sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share Alison Stopeck10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Alison Stopeck sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alison Stopeck sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this Alison Stopeck page

3 registered trials is a research-attention snapshot, not an endorsement of Alison Stopeck or any single study.

  • 1 of Alison Stopeck's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Locally Advanced Breast Cancer is the condition Alison Stopeck studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alison Stopeck pipeline card: 3 registered trials from official public datasets.Report a data error.